In the future, the activity of chemoimmunotherapy and combinations of TKIs with chemotherapy, anti VEGF/VEGFR agents, and/or immunotherapy in patients with BRAF-mutated cancers needs to be determined. The gene discussed is KDR; the disease is cancer.